Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Intraductal carcinoma of prostate: a comprehensive and concise review.

Roberts JA, Zhou M, Park YW, Ro JY.

Korean J Pathol. 2013 Aug;47(4):307-15. doi: 10.4132/KoreanJPathol.2013.47.4.307. Epub 2013 Aug 26. Review. Erratum in: Korean J Pathol. 2013 Oct;47(5):502. Park, Yong Wok [corrected to Park, Yong Wook].

2.

Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.

Miyai K, Divatia MK, Shen SS, Miles BJ, Ayala AG, Ro JY.

Int J Clin Exp Pathol. 2014 Apr 15;7(5):2518-26. eCollection 2014.

3.

ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia.

Han B, Suleman K, Wang L, Siddiqui J, Sercia L, Magi-Galluzzi C, Palanisamy N, Chinnaiyan AM, Zhou M, Shah RB.

Am J Surg Pathol. 2010 Apr;34(4):478-85. doi: 10.1097/PAS.0b013e3181d6827b.

PMID:
20220513
4.

Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion.

Miyai K, Divatia MK, Shen SS, Miles BJ, Ayala AG, Ro JY.

Hum Pathol. 2014 Aug;45(8):1572-81. doi: 10.1016/j.humpath.2014.03.011. Epub 2014 Apr 12.

PMID:
24842280
5.

Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance.

Guo CC, Epstein JI.

Mod Pathol. 2006 Dec;19(12):1528-35. Epub 2006 Sep 15.

6.

Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists.

Iczkowski KA, Egevad L, Ma J, Harding-Jackson N, Algaba F, Billis A, Camparo P, Cheng L, Clouston D, Comperat EM, Datta MW, Evans AG, Griffiths DF, Guo CC, Hailemariam S, Huang W, Humphrey PA, Jiang Z, Kahane H, Kristiansen G, La Rosa FG, Lopez-Beltran A, MacLennan GT, Magi-Galluzzi C, Merrimen J, Montironi R, Osunkoya AO, Picken MM, Rao N, Shah RB, Shanks JH, Shen SS, Tawfik OW, True LD, Van der Kwast T, Varma M, Wheeler TM, Zynger DL, Sahr N, Bostwick DG.

Ann Diagn Pathol. 2014 Dec;18(6):333-42. doi: 10.1016/j.anndiagpath.2014.08.010. Epub 2014 Sep 3.

PMID:
25263387
7.

Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies.

Shah RB, Magi-Galluzzi C, Han B, Zhou M.

Am J Surg Pathol. 2010 Apr;34(4):470-7. doi: 10.1097/PAS.0b013e3181cfc44b.

PMID:
20182345
8.

Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.

Haffner MC, Weier C, Xu MM, Vaghasia A, Gürel B, Gümüşkaya B, Esopi DM, Fedor H, Tan HL, Kulac I, Hicks J, Isaacs WB, Lotan TL, Nelson WG, Yegnasubramanian S, De Marzo AM.

J Pathol. 2016 Jan;238(1):31-41. doi: 10.1002/path.4628. Epub 2015 Oct 14.

9.

Intraductal carcinoma of the prostate.

Robinson B, Magi-Galluzzi C, Zhou M.

Arch Pathol Lab Med. 2012 Apr;136(4):418-25. doi: 10.5858/arpa.2011-0519-RA. Review.

PMID:
22458904
10.

Intraductal carcinoma of the prostate: the whole story.

Zhou M.

Pathology. 2013 Oct;45(6):533-9. doi: 10.1097/PAT.0b013e3283653322. Review.

PMID:
24018805
11.

Atypical cribriform lesions of the prostate: clinical significance, differential diagnosis and current concept of intraductal carcinoma of the prostate.

Shah RB, Zhou M.

Adv Anat Pathol. 2012 Jul;19(4):270-8. doi: 10.1097/PAP.0b013e31825c6c0e. Review.

PMID:
22692290
12.

Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate.

Hickman RA, Yu H, Li J, Kong M, Shah RB, Zhou M, Melamed J, Deng FM.

Am J Surg Pathol. 2017 Apr;41(4):550-556. doi: 10.1097/PAS.0000000000000794.

PMID:
28009609
13.

Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression.

Dawkins HJ, Sellner LN, Turbett GR, Thompson CA, Redmond SL, McNeal JE, Cohen RJ.

Prostate. 2000 Sep 1;44(4):265-70.

PMID:
10951489
14.

Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists.

Varma M, Egevad L, Algaba F, Berney D, Bubendorf L, Camparo P, Comperat E, Erbersdobler A, Griffiths D, Grobholz R, Haitel A, Hulsbergen-van de Kaa C, Langner C, Loftus B, Lopez-Beltran A, Mayer N, Nesi G, Oliveira P, Oxley J, Rioux-Leclercq N, Seitz G, Shanks J, Kristiansen G.

J Clin Pathol. 2016 Oct;69(10):852-7. doi: 10.1136/jclinpath-2016-203658. Epub 2016 Feb 29.

PMID:
26926101
15.

Intraductal Carcinoma of the Prostate Gland: Recent Advances.

Divatia MK, Ro JY.

Yonsei Med J. 2016 Sep;57(5):1054-62. doi: 10.3349/ymj.2016.57.5.1054. Review.

16.

ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma.

Morais CL, Guedes LB, Hicks J, Baras AS, De Marzo AM, Lotan TL.

Hum Pathol. 2016 Sep;55:117-25. doi: 10.1016/j.humpath.2016.04.017. Epub 2016 May 14.

PMID:
27189342
17.

Histopathological features of intra-ductal carcinoma of prostatic and high grade prostatic intraepithelialneoplasia and correlation with PTEN and P63.

Torabi-Nezhad S, Malekmakan L, Mashayekhi M, Daneshian A.

Prostate. 2016 Mar;76(4):394-401. doi: 10.1002/pros.23130. Epub 2015 Dec 8.

PMID:
26643011
18.

Prostatic Adenocarcinoma, Prostatic Intraepithelial Neoplasia, and Intraductal Carcinoma.

Zhou M, Magi-Galluzzi C.

Surg Pathol Clin. 2008 Dec;1(1):43-75. doi: 10.1016/j.path.2008.08.001. Epub 2008 Dec 6. Review.

PMID:
26837902
19.

Intraductal carcinoma of the prostate: precursor or aggressive phenotype of prostate cancer?

Bonkhoff H, Wheeler TM, van der Kwast TH, Magi-Galluzzi C, Montironi R, Cohen RJ.

Prostate. 2013 Mar;73(4):442-8. doi: 10.1002/pros.22579. Epub 2012 Sep 4. Review.

PMID:
22949099
20.

Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate.

Bettendorf O, Schmidt H, Staebler A, Grobholz R, Heinecke A, Boecker W, Hertle L, Semjonow A.

Genes Chromosomes Cancer. 2008 Jul;47(7):565-72. doi: 10.1002/gcc.20560.

PMID:
18383208

Supplemental Content

Support Center